GlassScriptPhysician profile
Timothy P Kelly
NPI 1164193751
$10,490.47
in general payments reported to CMS, 2019-2025
23 companies · $4,260 in 2025
The $4,260 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $641 · 2023: $2,245 · 2024: $3,345 · 2025: $4,260.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,886 · Education: $589 · Consulting Fee: $375.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,886.31 |
| Education | $588.53 |
| Consulting Fee | $375.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,673.83 | 2023-2025 | Tremfya |
| Abbvie INC. | $1,608.44 | 2022-2025 | |
| Leo Pharma INC. | $1,131.52 | 2022-2025 | Adbry, Anzupgo |
| Regeneron Healthcare Solutions, INC. | $868.14 | 2022-2025 | Dupixent, Libtayo |
| Amgen INC. | $828.92 | 2023-2025 | Otezla, Otezla |
| Lilly USA, LLC | $713.10 | 2022-2025 | Taltz, Ebglyss, Olumiant |
| Sun Pharmaceutical Industries INC. | $644.83 | 2022-2025 | Ilumya, Winlevi |
| Galderma Laboratories, L.P. | $540.37 | 2024-2025 | Nemluvio, Aklief |
| Ucb, INC. | $539.14 | 2022-2025 | Bimzelx, Cimzia |
| Genzyme Corporation | $427.52 | 2022-2025 | |
| Arcutis Biotherapeutics, INC. | $367.39 | 2024-2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $277.29 | 2023-2025 | |
| Organon LLC | $190.81 | 2025 | Vtama, Renflexis, Hadlima |
| Botanix Sb INC | $161.52 | 2025 | Sofdra |
| Sanofi-Aventis U.S. LLC | $133.99 | 2024-2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $109.99 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $89.41 | 2023-2024 | Sotyktu |
| Incyte Corporation | $57.55 | 2023-2025 | Opzelura |
| Verrica Pharmaceuticals INC. | $44.54 | 2025 | Ycanth |
| Kyowa Kirin, INC. | $28.12 | 2024 | Poteligeo |
| Dermavant Sciences, INC. | $22.46 | 2024 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.46 | 2024 | Cyltezo |
| Strata Skin Sciences, INC. | $14.13 | 2025 | Xtrac |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Kelly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.